Skip to main content
TipRanks
Go Ultimate75% OFF

PTC Therapeutics (P91) Q3 2026 Earnings Report

1 Followers

CH:P91 Q3 2026 EPS Results

Actual EPS
-CHF 0.51
Consensus EPS
CHF 0.12
Beat/Miss
Missed by -CHF 0.63
One Year Ago EPS
CHF 0.16

CH:P91 Q3 2026 Revenue Results

Actual Revenue
CHF 293.31M
Expected Revenue
CHF 251.19M
Beat/Miss
Beat by +CHF 42.11M
YoY Revenue Growth
+69.57%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/29/2026
Time
After Close
Conference Call
Thursday, October 29, 2026
CH:P91 Upcoming Earnings

PTC Therapeutics's next earnings date is estimated for February 23, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

CH:P91 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 29, 2026|% Change Since:―|
Earnings Call Sentiment|Positive

The call was strongly positive, driven by record product revenue, a more than 100% year-over-year increase in product revenue, raised 2026 guidance, strong Sephience launch momentum, a large remaining PKU opportunity, progress across the pipeline and a strengthened cash position. The main challenges were generic pressure on Emflaza, the lack of expected repeat government orders for Translarna in the fourth quarter, pending international reimbursement decisions, cumulative Sephience discontinuations in the low 20% range and the delayed votoplam FDA meeting. Highlights significantly outweighed lowlights.

Company Guidance

PTC Therapeutics raised full year 2026 product revenue guidance to $960 million to $990 million and now expects total revenue of $1.29 billion to $1.32 billion, representing 64% to 69% year-over-year product revenue growth, and expects to achieve cash flow breakeven in 2026; international revenue is expected to continue to grow with acceleration points as access and reimbursement are achieved in additional countries over the course of 2027, ST-920’s rolling BLA submission is expected to be completed in Q4 2026 with the potential for approval and commercial launch in 2027, the votoplam Type C meeting is now planned for the first quarter of 2027 and INVEST-HD is planned to enroll approximately 770 early symptomatic patients, PROVE-FA is expected to enroll approximately 120 individuals between 7 and 21 years of age, pricing and reimbursement in France, Italy and Spain are anticipated to be finalized somewhere in the first half of 2027, PTC303 is on schedule to enter the clinic in 2027, and the company believes ST-920 could be accretive in 2027 and remains confident in the $2 billion-plus peak sales opportunity for Sephience.

  • Record Revenue and Raised 2026 GuidanceThird-quarter total revenue was $358 million, including $276 million of product revenue, which increased over 100% from $131 million in the third quarter of 2025. The company raised full-year 2026 product revenue guidance to $960 million to $990 million and total revenue guidance to $1.29 billion to $1.32 billion, representing 64% to 69% year-over-year product revenue growth. Management expects to achieve cash flow breakeven in 2026.
  • Sephience Delivered Strong Global Launch PerformanceWorldwide Sephience revenue was $182 million in the third quarter, representing over 20% growth from the second quarter of 2026. More than 2,000 patients were actively receiving Sephience worldwide as of September 30, with continued quarter-over-quarter growth in the U.S. and international markets.
  • Large Remaining Sephience OpportunityManagement stated that the vast majority of approximately 17,000 U.S. PKU patients and approximately 58,000 individuals with PKU in target markets worldwide have not yet tried Sephience. The company remains confident in a $2 billion-plus peak sales opportunity, with continued growth expected from therapy-naive patients, Kuvan switchers, newborns and children, and patients with more severe PKU.
  • Strong Sephience Patient Demand and BenefitsU.S. demand remained strong across patient segments, including an uptick in branded and generic Kuvan switches and continued penetration into therapy-naive and tried-and-failed patients. Management reported strong adherence and patient benefits including diet liberalization, cognitive function and mood improvements. Patients switching from Kuvan showed further phenylalanine reductions and increased protein intake in the AMPLIPHY extension study, with the company citing approximately 100% greater natural protein intake on average for switchers.
  • International Sephience ExpansionInternational growth was led by the launch in Japan and new patient access through programs in several regions, including the Middle East, North Africa, Latin America and Canada. The company expects additional growth as pricing, reimbursement and access are secured in Europe, Latin America, the Middle East, Russia and the Commonwealth of Independent States during 2027 and beyond.
  • Strong Commercial Infrastructure and Launch InitiativesAll U.S. centers of excellence are prescribing Sephience, and teams are using claims data, center-specific approaches, digital programs and a new Ambassador program to deepen penetration. The company is also using physician-led studies, peer-to-peer patient sharing and real-world evidence to support adoption across the full PKU severity spectrum.
  • Mature Product Revenue ContributionThe DMD franchise generated $74 million of third-quarter product revenue. Emflaza generated $25 million despite multiple generics in the market, while Translarna generated $49 million, supported by sales in Europe, Latin America, the Middle East and North Africa and a Russian government purchase order.
  • Royalty Revenue and Cash PositionRoche reported approximately $607 million of global third-quarter Evrysdi revenue, resulting in $82 million of royalty revenue for PTC. Cash, cash equivalents and marketable securities totaled $2.13 billion as of September 30, 2026, compared with $1.95 billion as of December 31, 2025.
  • ST-920 Fabry Gene Therapy AcquisitionPTC acquired the BLA-stage ST-920 Fabry disease gene therapy asset for an upfront payment of $111 million, with up to $100 million in contingent milestone payments tied to U.S. regulatory approval. The company expects to complete the rolling BLA submission in the fourth quarter of 2026, with potential approval and commercial launch in 2027, and believes the transaction could be accretive in 2027.
  • ST-920 Clinical and Commercial PotentialData collected to date showed that ST-920 significantly increased alpha-Gal A activity, decreased lyso-Gb3, and improved renal function and other aspects of Fabry disease. The company reported a favorable safety profile with no serious adverse events related to hepatotoxicity or other immune reactions. PTC is preparing its U.S. commercial launch, including market-access work and engagement with a U.S. Fabry population described as over 11,000 patients.
  • Progress in Votoplam Huntington's Disease ProgramEnrollment is continuing in the global Phase III INVEST-HD trial of votoplam, which is planned to enroll approximately 770 early symptomatic patients. The primary endpoint is change in cUHDRS from baseline through 36 months, with an interim analysis planned for efficacy and futility. Sites are open globally, and the Type C meeting with FDA to discuss the data package and a potential accelerated-approval path is planned for the first quarter of 2027.
  • Vatiquinone PROVE-FA Trial InitiatedPTC initiated the global PROVE-FA trial of vatiquinone in the third quarter as expected. The single-arm study includes a well-matched natural-history comparator arm and is intended to support NDA resubmission. It is expected to enroll approximately 120 individuals aged 7 to 21, with mFARS as the primary endpoint; the study design, protocol and statistical plan were reviewed by FDA before initiation.
  • Advancement of Earlier-Stage PipelinePTC initiated a Phase IIa study of PTC844, its next-generation oral DHODH inhibitor, to evaluate the relationship between dose, DHODH inhibition and immune biomarkers in adults with rheumatoid arthritis. The Phase I study of PTC612, an oral NLRP3 inhibitor, is progressing with several SAD and MAD cohorts dosed, including a cohort with inflammation and cardiovascular disease. PTC303, an oral splicing candidate targeting MSH3 for disorders including DM1 and Huntington's disease, remains on schedule to enter the clinic in 2027.
  • Operating Expense ManagementThird-quarter non-GAAP R&D expense was $95 million, excluding $11 million of noncash stock-based compensation, compared with $91 million excluding $9 million in the prior-year quarter. Non-GAAP SG&A expense was $67 million, excluding $13 million of noncash stock-based compensation, compared with $74 million excluding $10 million in the prior-year quarter.
  • Potentially Favorable Rare-Disease Regulatory EnvironmentManagement expressed support for FDA discussions emphasizing greater flexibility, CBER-CDER alignment and bespoke approaches for rare-disease therapies. The company stated that ST-920 has RMAT designation, which provides potential for priority review.

CH:P91 Earnings History

CH:P91 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 23, 20272026 (Q4)0.28--1.37――
Oct 29, 20262026 (Q3)0.12-0.510.16-410.00% (-0.67)
Jul 30, 20262026 (Q2)0.190.75-0.68210.84% (+1.43)
May 07, 20262026 (Q1)-0.39-0.028.23-100.30% (-8.25)
Feb 19, 20262025 (Q4)0.08-1.37-0.7-96.47% (-0.67)
Nov 04, 20252025 (Q3)-0.930.16-1.14114.39% (+1.30)
Aug 07, 20252025 (Q2)-0.84-0.68-1.0635.66% (+0.38)
May 06, 20252025 (Q1)-0.838.23-0.98936.67% (+9.21)
Feb 27, 20252024 (Q4)-0.44-0.70-1.6958.74% (+0.99)
Nov 07, 20242024 (Q3)-1.25-1.14-1.4421.02% (+0.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed